ICML 2021 | Treating relapse in HL
Igor Aurer
• 7 Jun 2021
Igor Aurer, MD, PhD, University of Zagreb, Zagreb, Croatia, describes the optimal management of relapse in Hodgkin’s lymphoma (HL). Current treatment guidelines for treating HL differ in Europe and America, which may be attributed to the lack of Phase III trials assessing the efficacy of newer treatments such as brentuximab vedotin, or PD-1 blockers as second-line therapy. Prof. Aurer recommends brentuximab vedotin or PD-1 blockers with existing chemotherapy regimens followed by autologous stem cell transplant, as well as radiotherapy for patients with relapsed/refractory HL. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).
